Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target

Benzinga Newsdesk www.benzinga.com Positive 88.4%

Neg 0% Neu 0% Pos 88.4%

Wolfe Research analyst Alexandria Hammond upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outperform and announces $300 price target.